CSL is trading 17.3% up at $28.10 after investors continued buying following August 18 FY2026 results.
- Despite a $2.6 billion statutory loss from impairments and restructuring, underlying earnings beat expectations; management forecast approximately 5% FY2027 profit growth.
- CSL authorized a $1.1 billion share buyback; Reuters said results and plasma outlook drove its strongest intraday rally since 2001.
- Company-driven, with biotech-sector support; trading is active in the August 19 session, extending the prior day’s substantial rally.